A Phase 2/3 study of anti-Fel d 1 monoclonal antibodies (freneslerbart and mevonlerbart) in adults and children with cat allergy-related eye symptoms
Recruiting Phase 3 NCT07675811
Study Description
A study testing two new medicines, freneslerbart and mevonlerbart (alone or combined as 'REGN-2Cat'), to see if they can safely reduce eye allergy symptoms caused by cat hair and dander in adults and children
Study Details
- Registry ID:
- NCT07675811
- Conditions:
- Allergic Conjunctivitis
- Phase:
- Phase 3
- Target Enrollment:
- 570 participants
- Start Date:
- Age Range:
- 8–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Andover Eye Associates
Andover, Massachusetts, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.